Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Little is known about tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity in human immunodeficiency virus (HIV)-infected patients in Korea. The objective of this study was to evaluate the incidence and risk factors of TDF-associated nephrotoxicity among HIV-infected patients in Korea. Methods: A single-center retrospective cohort study was conducted on HIVinfected patients in Korea. We included patients who had started TDF or abacavir (ABC)-based antiretroviral therapy (ART) between October 2006 and December 2014. Estimated glomerular filtration rate (eGFR) was estimated using the Chronic Kidney Disease-Epidemiology Collaboration equation. Renal dysfunction was defined as > 25% decrease of baseline eGFR. A propensity matched case-control study was conducted to compare renal dysfunction rates between the two groups. The risk factors of nephrotoxicity were analyzed by Cox regression analysis. Results: A total of 210 HIV-infected patients were included in the study, of which, 108 were TDF-based ART group and 102 were ABC-based ART group. Renal dysfunction occurred in 16 patients (14.8%) in the TDF group and 11 (10.8%) in the ABC group. Incidence of renal dysfunction of TDF and ABC group was 9.66 per 100 person-years (PYs) and 5.14 per 100 PYs, respectively (p = 0.176). In propensityscore- matched analysis, renal dysfunction rates were TDF 13.3% versus ABC 13.3% (p > 0.999). In multivariable analysis, Centers for Disease Control and Prevention clinical category C was a significant risk factor for renal dysfunction. Conclusions: Approximately, 13% of HIV-infected patients treated with TDF had renal dysfunction. Advanced stage of HIV infection was a significant risk factor for renal dysfunction.
Abstract
Background/Aims: Little is known about tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity in human immunodeficiency virus (HIV)-infected patients in Korea. The objective of this study was to evaluate the incidence and risk factors of TDF-associated nephrotoxicity among HIV-infected patients in Korea. Methods: A single-center retrospective cohort study was conducted on HIVinfected patients in Korea. We included patients who had started TDF or abacavir (ABC)-based antiretroviral therapy (ART) between October 2006 and December 2014. Estimated glomerular filtration rate (eGFR) was estimated using the Chronic Kidney Disease-Epidemiology Collaboration equation. Renal dysfunction was defined as > 25% decrease of baseline eGFR. A propensity matched case-control study was conducted to compare renal dysfunction rates between the two groups. The risk factors of nephrotoxicity were analyzed by Cox regression analysis. Results: A total of 210 HIV-infected patients were included in the study, of which, 108 were TDF-based ART group and 102 were ABC-based ART group. Renal dysfunction occurred in 16 patients (14.8%) in the TDF group and 11 (10.8%) in the ABC group. Incidence of renal dysfunction of TDF and ABC group was 9.66 per 100 person-years (PYs) and 5.14 per 100 PYs, respectively (p = 0.176). In propensityscore- matched analysis, renal dysfunction rates were TDF 13.3% versus ABC 13.3% (p > 0.999). In multivariable analysis, Centers for Disease Control and Prevention clinical category C was a significant risk factor for renal dysfunction. Conclusions: Approximately, 13% of HIV-infected patients treated with TDF had renal dysfunction. Advanced stage of HIV infection was a significant risk factor for renal dysfunction.
참고문헌 (18)
- Karras A, "Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients : three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus", Clin Infect Dis, 36, pp.1070~1073 (2003)
- Zimmermann AE, "Tenofovir-associated acute and chronic kidney disease : a case of multiple drug interactions", Clin Infect Dis, 42, pp.283~290 (2006)
- Perrot S, "Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient", J Clin Rheumatol, 15, pp.72~74 (2009)
- Perazella MA, "Tenofovir-induced kidney disease : an acquired renal tubular mitochondriopathy", Kidney Int, 78, pp.1060~1063 (2010)
- Gervasoni C, "Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events", PLoS One, 8, pp.e80242~ (2013)
- Nishijima T, "Renal function declines more in tenofovir-than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection", PLoS One, 7, pp.e29977~ (2012)
- Nishijima T, "Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients : a retrospective cohort study of Japanese patients", PLoS One, 6, pp.e22661~ (2011)
- Marchewka Z, "Comorbidities as risk factors of chronic kidney disease in HIV-infected persons", Postepy Hig Med Dosw(Online), 69, pp.1364~1370 (2015)
- Pinto Neto LF, "Nephrotoxicity during tenofo-vir treatment : a three-year follow-up study in a Brazilian reference clinic", Braz J Infect Dis, 20, pp.14~18 (2016)
- Kearney BP, "Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir", ritonavir, 2006, pp.43, 278~283
- Gallant JE, "Renal function with use of a tenofovir-containing initial antiretroviral regimen", AIDS, 23, pp.1971~1975 (2009)
- Goicoechea M, "Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy", J Infect Dis, 197, pp.102~108 (2008)
- Misuk Ji, "Comparing Results of Five Glomerular Filtration Rate-Estimating Equations in the Korean General Population: MDRD Study, Revised Lund-Malmӧ, and Three CKD-EPI Equations", Annals of Laboratory Medicine, 36(6), pp.521~528 (2016), 대한진단검사의학회
- Centers for Disease Control and Prevention, "Update:impact of the expanded AIDS surveillance case definition for adolescents and adults on case reporting. United States, 1993", MMWR Morb Mortal Wkly Rep, 43, pp.160~161 (1994)[DOI]
- Rodriguez-Novoa S, "Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir : a pharmacogenetic study", Clin Infect Dis, 48, pp.e108~e116 (2009)
- Cooper RD, "Systematic review and meta-analysis : renal safety of tenofovir disoproxil fumarate in HIV-infected patients", Clin Infect Dis, 51, pp.496~505 (2010)
- 진선, "The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg", dL among the Patients Treated with Tenofovir, Infection and Chemotherapy, pp.2015, 47(4)[DOI]
- Rotheram-Borus MJ, "The past, present, and future of HIV prevention : integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention", Annu Rev Clin Psychol, 5, pp.143~167 (2009)